You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 634 EVEREST-1: A seamless phase 1/2 study of CEA logic-gated Tmod CAR T-cell therapy (A2B530) in patients with solid tumors associated with CEA expression also exhibiting HLA loss of heterozygosity (LOH)

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
634 EVEREST-1: A seamless phase 1/2 study of CEA logic-gated Tmod CAR T-cell therapy (A2B530) in patients with solid tumors associated with CEA expression also exhibiting HLA loss of heterozygosity (LOH)

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023266020
Dec 202398013
Jan 202410308
Feb 202478013
Mar 2024136011
Apr 202494012
May 202478020
Jun 2024115012
Jul 2024156015
Aug 202496012
Sep 20249605
Oct 20248006
Nov 202410006
Dec 2024140017
Jan 2025175024
Feb 202534029
Mar 20250012
Apr 2025008
May 2025009
Jun 2025206
Total18470258